United States Intravenous Solutions Market Insights Forecasts to 2033

• The U.S. Intravenous Solutions Market Size was valued at USD 3.01 Billion in 2023.
• The Market is growing at a CAGR of 7.41% from 2023 to 2033
• The U.S. Intravenous Solutions Market Size is expected to reach USD 6.15 Billion by 2033

The United States Intravenous Solutions Market is anticipated to exceed USD 6.15 Billion by 2033, growing at a CAGR of 7.41% from 2023 to 2033. The growing prevalence of chronic respiratory diseases and rising launched & regulatory approvals for IV injections are driving the growth of the intravenous solutions market in the US.       

Market Overview

Intravenous (IV) solutions are a sterile liquid that is a comprehensive blend of vital nutrients supporting electrolyte imbalance treatment, fluid balance maintenance, and replenishment of lost fluid. They are made of water and various quantities of electrolytes, sugar, or drugs based on the age, body size, and medical condition of the patient. They are administered directly into the bloodstream via a vein. Patients suffering from diabetes, cancer, and other similar illnesses can receive nutrients from these solutions. Manufacturers are developing new, advanced products like premixed solutions, which improve convenience and cut down on packaging waste. The availability of solutions in portable packages makes it easier for patients to use the drips in the comfort of their own homes rather than in a hospital, and product innovations like premixed solutions, improve convenience and reduce packaging waste.  

Report Coverage

This research report categorizes the market for the US intravenous solutions market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United States intravenous solutions market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the US intravenous solutions market.

Driving Factors

The rising incidence of illnesses and the rising number of surgeries are responsible for driving the market expansion. Additionally, the growing number of elderly people who are vulnerable to non-communicable diseases like cancer, neurological disorders, cardiovascular disorders, and spinal injuries is anticipated to drive the market growth. The number of cancer cases in the United States is expected to surpass 2 million, according to a report released by the American Cancer Society. The requirement for parenteral nutrition products comprising glutamine, phospholipids, glucose, and amino acids is increased due to the weakened immune system associated with cancer. Thus, the increasing prevalence of cancer is predicted to drive the market demand for intravenous solutions.

Restraining Factors

It is anticipated that the intravenous fluid products recall impedes market expansion of intravenous solutions. Intravenous fluids are regulated as pharmaceutical products and require all the capital investment requirements of sterile injectable drugs, which hinders the market's growth.

Market Segmentation

The United States Intravenous Solutions Market share is classified into type and nutrients.

• The total parenteral nutrition (TPN) segment dominates the market with the largest market share in 2023.

The United States intravenous solutions market is segmented by type into total parenteral nutrition (TPN) and peripheral parenteral nutrition (PPN). Among these, the total parenteral nutrition (TPN) segment dominates the market with the largest market share in 2023. TPN is the practice of delivering an entire spectrum of nutrients via IV route that are frequently utilized in surgical intensive care units (ICUs). The increasing number of hospitalizations in the region is driving the market demand for TPN intravenous solutions.

• The single-dose amino acids segment dominated the US intravenous solutions market with the largest revenue share in 2023.       

Based on the nutrients, the U.S. intravenous solutions market is divided into carbohydrates, vitamins & minerals, single-dose amino acids, parenteral lipid emulsion, and others. Among these, the single-dose amino acids segment dominated the US intravenous solutions market with the largest revenue share in 2023. Various research indicates that amino acid single-doses offer a comprehensive source of protein. The convenient use of a combination of IV solutions with other parenteral formulations for delivery is driving the market growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the U.S. intravenous solutions market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Fresenius Kabi AG
• Baxter
• JW Life Science
• B. Braun Medical Inc
• Amphastar Pharmaceuticals, Inc.
• Grifols USA, LLC
• ICU Medical, Inc.
• Athenex, Inc.
• Pfizer Inc.
• Rockwell Medical, Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In February 2024, B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced the launch of its new Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL), the fifth product in its portfolio of Heparin premixed bags.
• In March 2022, Fresenius Kabi announced it has been granted an expanded indication for SMOFlipid Lipid Injectable Emulsion (ILE) for pediatric patients in the United States, including term and preterm neonates, making it the first and only four-oil lipid emulsion for parenteral nutrition patients of every age.

Market Segment

This study forecasts revenue at U.S., regional, and country levels from 2020 to 2033. Spherical Insights has segmented the United States Intravenous Solutions Market based on the below-mentioned segments:

US Intravenous Solutions Market, By Type

• Total Parenteral Nutrition (TPN)
• Peripheral Parenteral Nutrition (PPN)

US Intravenous Solutions Market, By Nutrients

• Carbohydrates
• Vitamins & Minerals
• Single-Dose Amino Acids
• Parenteral Lipid Emulsion
• Others